Description: Biocure Technology Inc. develops and commercializes biosimilar pharmaceutical products in South Korea. The company is developing Interferon Beta 1b for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It is also developing a foot and mouth disease vaccine, a hair growth production product, and a breast cancer detection kit. Biocure Technology Inc. is headquartered in Vancouver, Canada.
Home Page: www.biocuretech.com
1055 West Hastings Street
Vancouver,
BC
V6E 2E9
Canada
Phone:
604 609 7146
Officers
| Name | Title |
|---|---|
| Dr. Björn Cochlovius Ph.D. | President |
| Mr. Konstantin Lichtenwald B.B.A., CPA, CGA | CFO, Corporate Secretary & Director |
| Mr. Yee Sing Cheng | CEO & Director |
| Mr. Marco Nonni | Consultant |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 5.25 |
| Price-to-Book MRQ: | 2.8847 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |